Effect of trimetazidine on cardiac function and exercise tolerance in hypertension patients with diabetic.
- Author:
Pingxian YE
1
;
Pingzhen YE
1
;
Jinping HE
1
Author Information
1. Department of Cardiology, Zhejiang Jinhua Guangfu Hospital, Jinhua 321000, Zhejiang Province, China.
- Publication Type:Journal Article
- MeSH:
Diabetes Complications;
complications;
Diabetes Mellitus;
drug therapy;
Double-Blind Method;
Exercise Tolerance;
drug effects;
Heart;
drug effects;
Humans;
Hypertension;
complications;
drug therapy;
Natriuretic Peptide, Brain;
blood;
Prospective Studies;
Treatment Outcome;
Trimetazidine;
pharmacology;
therapeutic use;
Vasodilator Agents;
pharmacology;
therapeutic use
- From:
Journal of Zhejiang University. Medical sciences
2019;48(3):282-288
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To determine the effect of trimetazidine on cardiac function and exercise tolerance in primary hypertension patients with type 2 diabetic.
METHODS:In this randomized, double-blind, placebo-controlled prospective study, 60 primary hypertensive patients with diabetic were equally assigned into two groups, patients received trimetazidine (20 mg, 3 times a day) or placebo for 1 year. Echocardiography, cardiopulmonary exercise testing were performed; and the plasma N terminal pro B type natriuretic peptide (NT-ProBNP), hr-CRP, TNF-α, angiotensin Ⅱ and endothelin concentration were determined before and after treatment.
RESULTS:In trimetazidine group, the left ventricular mass index, the mitral flow velocity E wave to A wave ratio (E/A), the peak early diastolic velocity (V) to late diastolic velocity (V) ratio (V/V) and the peak systolic velocity (Vs) were significantly improved, the plasma NT-ProBNP level was significantly decreased, and the exercise time, metabolic equivalent, maximal oxygen uptake and anaerobic threshold were significantly increased (all <0.05); plasma concentration of hr-CRP, TNF-α, angiotensin Ⅱ and endothelin were significantly reduced after trimetazidine treatment, compared with baseline (all <0.05) and with placebo (all <0.05). There were no significant differences in any of above parameters after treatment in placebo group (all >0.05). No severe adverse reaction was observed in both groups.
CONCLUSIONS:For patients with both hypertension and diabetes, trimetazidine can improve cardiac function and increase exercise tolerance.
